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a renewed interest for angiographic risk stratiﬁcation in patients undergoing percutaneous coronary intervention.
Syntax score is based on qualitative and quantitative characterization of coronary artery disease by including
11 angiographic variables that take into consideration lesion location and characteristics. Thus far, this score has
been shown to be an effective tool to risk-stratify patients with complex coronary artery disease undergoing
percutaneous coronary intervention in the landmark SYNTAX trial, as well as in other clinical settings. This review
provides an overview of its current applications, including its integration with other nonangiographic clinical scores,
and explores future applications of the SYNTAX and derived scores. (J Am Coll Cardiol 2013;62:1219–30) ª 2013
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Cardiac Surgery) score (SS) was developed as part of the
SYNTAX trial with the object to characterize and objectively
quantify the severity and extent of coronary artery disease
(CAD) (1). Subsequent assessments of the SS both within
the SYNTAX trial and in external datasets have demon-
strated the score’s ability to predict adverse ischemic events in
patients undergoing percutaneous coronary intervention
(PCI) (2–4). The application of SS has been extended to
a variety of other clinical settings (3–22). Moreover, the
integration of clinical variables in the SS has provided
a signiﬁcant improvement in the process of risk stratiﬁcation
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2013.Before the SYNTAX Score
Prior to the development of the SS, several coronary
angiographic-based scores were created to risk-stratify patients
with CAD (31–39). Most of these early scores were elaborated
around the concept of quantiﬁcationofmyocardiumat risk and/
or severity of coronary artery stenosis. Among them, the Duke
Jeopardy score,ﬁrst described in1977 (31) and then validated in
1985 (32), demonstrated that a simplemethodof estimating the
amount of myocardium at risk on the basis of the particular
location of coronary artery stenosis gave more prognostic
information than the number of diseased coronary arteries did.
Furthermore, by including thedegree of coronary artery stenosis
and by attributing a higher score to the disease of the left
anterior descending coronary artery than to other coronary
arteries, the prognostic ability of this score was signiﬁcantly
improved. In 1988, the American College of Cardiology/
American Heart Association Task Force subcommittee
proposed a lesion-speciﬁc classiﬁcation as a guide to estimate
the likelihood of a successful balloon angioplasty and the
occurrence of complications (40–42). Lesions were classiﬁed as
types A, B, or C, based on the presence or absence of high-risk
angiographic characteristics (such as lesion length, tortuosity,
calciﬁcation, thrombus, bifurcation, total occlusion, etc.). Each
lesion type was associated with an estimated rate of procedural
success, deﬁned as freedom of abrupt vessel closure following
balloon angioplasty (procedural success with type A lesions:
>85%, type B: 60% to 85%, and type C: <60%). Although
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1220this score was initially applied
to predict outcomes after balloon
angioplasty, it was also shown to
predict outcomes after bare-metal
stent (43) or drug-eluting stent
implantation (44). The amount of
jeopardized myocardium and le-
sion high-risk features, as deter-
mined by coronary angiography,
have been the basis of many con-
temporary scores, including the
SS.
The SYNTAX Score
The SS is an anatomically based
tool that quantitatively charac-
terizes the coronary vasculature
with respect to the number, loca-
tion, complexity, and functional
impact of angiographically obs-
tructive lesions. The distributions
of the coronary arteries are map-
ped based on the ARTS (Arter-
ial Revascularization Therapies
Study) investigators’modiﬁcationronary Segment Classiﬁcation Used in the
gment classiﬁcation used in SYNTAX (Synergy Betwe
odiﬁed by the ARTS (Arterial Revascularization Therapof the American Heart Association classiﬁcation of coronary
tree segments (Fig. 1) (45,46). Each coronary segment is
weighted according to the fraction of blood supplied to the left
ventricle and the amount of corresponding jeopardized
myocardium, as devised by Leaman et al. (47) (Table 1). Each
signiﬁcant lesion (deﬁned as a diameter stenosis of 50% in
vessels with a minimum diameter of 1.5 mm) is visually
assessed and analyzed according to the American College of
Cardiology/American Heart Association lesion classiﬁcation
system (40). Depending on several angiographic characteris-
tics, the lesion is given a corresponding point value (Table 2),
and ﬁnally scores of individual lesions are summed to derive
the ﬁnal score. (The detailed method of score calculation is
described elsewhere [1], and it is outside the scope of this
review.) Whereas the derived score is a semicontinuous vari-
able, it is typically categorized in a tripartite fashion as
determined in the SYNTAX trial (low: 0 to 22, intermediate:
23 to 32, high: >32) (2).
Reproducibility of the SYNTAX Score
Assessment of the SS relies on visual quantiﬁcation of
diameter stenosis and a qualitative evaluation of the
morphological characteristics of each lesion, a process that
carries a well-described degree of variability (48,49). In the
study by Serruys et al. (50), overall core laboratorySS
en PCI With Taxus and Cardiac Surgery) score (SS), initially developed by American
ies Study) investigators. Adapted with permission from Sianos (1).
Table 1 Segmental Weighting Factors Used in SS
Segment Segment Name
Right
Dominance
Left
Dominance
1 RCA proximal 1 0
2 RCA mid 1 0
3 RCA distal 1 0
4 Posterior descending artery 1 N/A
16 Posterolateral branch from RCA 0.5 N/A
16a Posterolateral branch from RCA 0.5 N/A
16b Posterolateral branch from RCA 0.5 N/A
16c Posterolateral branch from RCA 0.5 N/A
5 Left Main 5 6
6 LAD proximal 3.5 3.5
7 LAD mid 2.5 2.5
8 LAD apical 1 1
9 First diagonal 1 1
9a First diagonal 1 1
10 Second diagonal 0.5 0.5
10a Second diagonal 0.5 0.5
11 Proximal circumﬂex artery 1.5 2.5
12 Intermediate/anterolateral artery 1 1
12a Obtuse marginal 1 1
12b Obtuse marginal 1 1
13 Distal circumﬂex artery 0.5 1.5
14 Left posterolateral 0.5 1
14a Left posterolateral 0.5 1
14b Left posterolateral 0.5 1
15 Left Posterior descending N/A 1
Adapted, with permission, from Leaman et al. (47); and adapted from Sianos et al. (1).
LAD ¼ left anterior descending artery; N/A ¼ not applicable; RCA ¼ right coronary artery;
SS ¼ SYNTAX score; SYNTAX ¼ Synergy Between PCI With Taxus and Cardiac Surgery.
Table 2 Points for Speciﬁc Lesion Characteristics in SS
Aorto ostial stenosis þ1
Bifurcation, Medina classiﬁcation*
Type 1-0-0, 0-1-0, 1-1-0 þ1
Type 1-1-1, 0-0-1, 1-0-1, 0-1-1 þ2
Angulation <70 þ1
Trifurcation
1 diseased segment þ3
2 diseased segments þ4
3 diseased segments þ5
4 diseased segments þ6
Diameter reduction
Total occlusion 5
Signiﬁcant lesion, 50% to 99% 2
TO
Age >3 months or unknown þ1
Blunt stump þ1
Bridging þ1
First segment visible beyond TO þ1/ nonvisible segment
SB
Yes, SB <1.5 mm þ1
Yes, SB both <1.5 mm & 1.5 mm þ1
Severe tortuosity þ2
Length >20 mm þ1
Heavy calciﬁcation þ2
Thrombus þ1
Diffuse disease/small vessels þ1/ segment number
*Medina classiﬁcation: 0 indicates absence of signiﬁcant lesion; 1 indicates presence of signiﬁcant
lesion. In the 3-digit code, the ﬁrst and second digits indicate the status of the parent vessel
proximal and distal to the side branch, respectively, and the third digit indicates the status of the
side branch itself. Adapted from Sianos et al. (1).
SB ¼ side branch; SS ¼ SYNTAX score; TO ¼ total occlusion.
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1221interobserver and intraobserver kappa values were 0.45 and
0.59, respectively, thereby indicating a moderate level of
agreement. The level of agreement for each speciﬁc SS
component (bifurcation, calciﬁcation severity, diffuse
disease, etc.) varied from 0.41 to 0.85, indicating a moderate
to good level of agreement. To better understand the sources
of inter- and intraobserver variability, our group demon-
strated that an extensive training provided by expert core
laboratory technicians can signiﬁcantly improve the scoring
performance and the level of agreement among a group of
interventional cardiologists (51). The SS components with
the most signiﬁcant variability were bifurcation lesions, small
vessel/diffuse disease, and lesions involving the circumﬂex
territory. In light of these ﬁndings, extensive training,
beyond the recommended online tutorial (52), is mandatory
for optimal clinical application.Role of the SYNTAX Score in
Various Clinical Settings
As shown in Table 3, the prognostic value of the SS has
been investigated in various clinical settings, including
patients with multivessel CAD, unprotected left main (LM)
CAD, non–ST-segment elevation acute coronary syndrome,
and ST-segment elevation acute myocardial infarction (MI).Multivessel CAD. TheSSwasﬁrst applied in the SYNTAX
trial that enrolled 1,800 patients with multivessel and/or
LM CAD (2). At 1-year follow-up, major adverse cardiovas-
cular and cerebrovascular events (MACCE), which included
all-cause death, MI, stroke, and target vessel revascularization
(TVR), were signiﬁcantly lower in the coronary artery bypass
graft (CABG) group (12.4%) compared with the PCI group
(17.8%, p ¼ 0.002). Interestingly, whereas 1-year MACCE
rates progressively increased across SS tertiles in patients
treated with PCI (MACCE rates in lower SS tertile¼ 14.7%,
intermediate SS tertile ¼ 16.7%, and higher SS tertile
¼ 23.4%), MACCE rates in patients treated with CABG
remained similar across all SS tertiles (lower SS tertile
¼ 13.6%, intermediate SS tertile ¼ 12.0%, and higher SS
tertile ¼ 10.9%). These results make the SS an effective
stratiﬁcation tool when deciding the optimal strategy of
revascularization between CABG and PCI. The recently
published 5-year results of the SYNTAX trial reinforced the
1-year ﬁndings, with the CABG cohort of patients having
signiﬁcantly lowerMACCErates in patientswithSS> 32 and
between 23 and 32 compared with the PCI cohort (53).
In contrast, in the FREEDOM (Future Revascularization
Evaluation in Patients With Diabetes Mellitus: Optimal
Management ofMultivesselDisease) trial (54), inwhich 1,900
diabetic patients with multivessel CAD were randomized to
Table 3 SS Use Among Different Populations
First Author (Ref. #) Year Type of Study N Follow-Up (months) Tertiles Outcomes Predicted Conclusions
Multivessel disease
Valgimigli et al. (4) 2007 RP, MC 306 12 18, >18–26,>26 MACCE SS identiﬁed as independent predictor of 1-yr MACCE;
best cutoff value for PCI was SS 32
Farkouh et al. (54) 2012 PP, MC 1,900 46 0–22, >22–32, >32 d d
Left main
Capodanno et al. (5) 2009 RP, SC 819 24 <34, >34* Death SS >34 identiﬁed as predictor of 2-yr death and MACE
after LM PCI, CABG should be the preferred treatment
for SS >34
Kim et al. (7) 2010 RP, MC 1,580 36 23, >23–36, >36 MAVE SS predicted 3-yr MAVE after PCI; highest tertile having
signiﬁcantly greater MAVE
Morice et al. (8) 2010 PP, MC 705 12 0–22, >22–32, >32 MACCE SS >32 was independent predictor of greater 1-yr
MACCE after PCI compared with CABG
Capodanno et al. (6) 2011 RP, SC 556 36 32y MAVE, MACCE PCI with SS 32 had similar MAVE compared with CABG
but greater MACCE due to more frequent TVR at 3 yrs
Chakravarty et al. (10) 2011 RP, SC 328 39.5 z Death, MACCE SS 36 and >20 were independent predictors of death
and MACCE, respectively, in the PCI group at 2.8 yrs
Park et al. (55) 2011 RP, MC 1,146 55.1 0–22, >22–32, >32 Death, MAVE SS 32 had lower or equal MAVE with PCI using DES and
those with SS >32 did better with CABG at 5 yrs
Shiomi et al. (11) 2012 RP, MC 1,005 34.2 0–22, >22–32, >32 MAVE SS 32 had equivalent MAVE compared with CABG and
those with SS >32 has lower MAVE with CABG at 3 yrs
LM/MVD
Serruys et al. (2) 2009 PP, MC 1,800 12 0–22, >22–32, >32 MACCE SS >32 had greater 1-yr MACCE with PCI compared
with CABG
STEMI
Garg et al. (14) 2011 RP, MC 807 12 9, >9–16, >16 Death, MACE, ST SS was independent predictor of 1-yr death, MACE,
and ST
Magro et al. (12) 2011 PP, MC 669 18 <10, 10–20, >20 Death, MACE SS was independent predictor of death and MACE
at 1.5 yrs
NSTE-ACS
Palmerini et al. (16) 2011 RP, MC 2,627 12 <7, >7–<13, 13 Death, cardiac death, MI, TVR SS was independent predictor of 1-yr death, MI, and TVR
All-comers
Wykrzykowska et al. (17) 2010 PP, MC 1,397 12 8, >8–16, >16 Death, TVR, ST SS was independent predictor of 1-yr death and MACE
Garg et al. (15) 2011 PP, MC 2,033 12 9, 9–17, >17 MACE, MI, TVR, TLR SS was independent predictor of 1-yr MACE, MI, TVR, and
TLR. Addition of clinical variables (ACEF score)
improved the score’s predictability
Garg et al. (13) 2011 RP, MC 6,496 12 8, >8–<15, 15–<23, 23x Death, MACE, MI, TVR, ST SS was independent predictor of 1-yr death, MACE, ST
Girasis et al. (27) 2011 RP, MC 848 60 7, >7–14, >14 Death, cardiac death, MACE, MI, TLR SS was independent predictor of MACE at 5 yrs, which
was further enhanced by addition of clinical variables
(ACEF score)
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Table 3 Continued
First Author (Ref. #) Year Type of Study N Follow-Up (months) Tertiles Outcomes Predicted Conclusions
Residual disease
Généreux et al. (69) 2012 RP, MC 2,686 12 0 –2, >2–8, >8 Death, cardiac death, MACE, MI, TVR rSS >8 was predictor of increased death, cardiac death,
MACE, MI, and TVR at 30 days and 1 yr in NSTE-ACS
patients
Capodanno et al. (72) 2013 RP, SC 400 24 0, 1–8, >8 Death rSS was independent predictor of cardiac death at 2 yrs
in LM PCI
Malkin et al. (70) 2012 RP, SC 353 36 0, >0 Death rSS was signiﬁcant predictor of 3-yr death in LM PCI
Malkin et al. (73) 2013 PP, SC 240 30 <1, 1–8, >8 Death rSS was independent predictor of death in MVD PCI at
2.6 yrs
Farooq et al. (71) 2013 PP, MC 903 60 0, >0–4, >4–8, >8 Death, cardiac death, MACCE,
stent thrombosis
rSS was an independent predictor of 5-yr mortality after
DES PCI of complex coronary disease, with a similar
effect among LM PCI, diabetes, and poor ejection
fraction.
CABG
Birim et al. (18) 2009 RP, SC 148 12 19, 19–25, >25 MACCE SS was independent predictor of 1-yr MACCE and SS
>36.5 was the best discriminating cutoff
Lemesle et al. (59) 2009 RP, SC 320 12 <24.5, 24.5–34, >34 d SS was unable to predict 1-yr MAVE after CABG
Mohr et al. (19) 2011 PP, MC 1,541 24 0–22, 22–32, >32 d SS was unable to predict 2-yr MACCE after CABG
Carnero-Alcazar et al. (20) 2011 RP, SC 716 26.68 <33, 33–37, >37 MACCE SS was independent predictor of 2-yr MACCE
Head et al. (21) 2012 PP, MC 836 36 0–22, 22–32, >32 d SS >32 showed a trend toward increasing 3-yr MACCE
*This study used 2 cutoff values rather than tertiles. yThis study included all patients with SS 32. zIn this study, patients were divided in quartiles. PCI group: quartile 1: 10 to 19; quartile 2: 19.5 to 24; quartile 3: 26 to 35; and quartile 4: 36 to 68.5. CABG group: quartile 1: 10
to 21; quartile 2: 22 to 27; quartile 3: 27 to 34; and quartile 4: 35 to 49. xPatients were divided in quartiles rather than tertiles.
ACEF ¼ Age, Creatinine, and Ejection Fraction score; CABG ¼ coronary artery bypass graft; DES ¼ drug-eluting stent(s); LM ¼ left main coronary artery disease; MACE ¼ major adverse cardiac event(s); MACCE ¼ major adverse cardiovascular and cerebrovascular event(s);
MAVE ¼major adverse vascular event(s); MC ¼multicenter; MI ¼myocardial infarction; MVD ¼multiple vessel disease; NSTE-ACS ¼ non–ST-segment elevation acute coronary syndrome; PCI ¼ percutaneous coronary intervention; PP ¼ prospective; RP ¼ retrospective; rSS ¼
residual SYNTAX score; SC ¼ single center; ST ¼ stent thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; other abbreviations as in Table 1.
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1224either PCI or CABG, no signiﬁcant interaction was apparent
between the strategy of revascularization and the SS for
1- and 5-year clinical outcomes (p for interaction ¼ 0.28 and
0.58, respectively). However, the interaction analysis in the
FREEDOM trial may have been underpowered. Moreover,
patients were stratiﬁed using the same tertile cutoff value as
in the SYNTAX trial; therefore, whether different cutoff
values could be associated with different outcomes remains
undetermined. Finally, a trend was apparent, suggesting that
the beneﬁt of CABG over PCI was less evident in patients in
the lowest SS tertile than in the upper 2 tertiles. Further studies
are warranted to determine the prognostic value of the SS in
patients with multivessel CAD and diabetes.
The largest pooled analysis investigating the prognostic value
of the SS, including 7 contemporary trials (n ¼ 6,508),
demonstrated that the SS was an independent predictor of
mortality, stent thrombosis, and combined ischemic endpoints
at 1 year, regardless of the clinical presentation (13). The rates
of these adverse events were signiﬁcantly greater in the highest
SS quartile.
Left main CAD. The prognostic value of the SS has been
extensively studied in patients with unprotected LM CAD
undergoing PCI (3,5–11,55). In most of these studies,
rates of composite ischemic endpoints (death, MI, target
lesion revascularization TLR, or TVR) were signiﬁcantly
greater in the highest tertile of SS than in the lower 2
tertiles (3,6,8–10). In a recent report, Capodanno et al. (5)
demonstrated that SS >34 was associated with signiﬁ-
cantly higher rates of ischemic events in patients undergoing
PCI than in those undergoing CABG. Interestingly, only
the baseline SS, and not even the lesion location in the LM
(ostial, shaft, or bifurcation) or number of stents implanted,
had a prognostic value. SS, therefore, currently has a central
role in selecting the most appropriate strategy of revascu-
larization between PCI and CABG in patients with
unprotected LM CAD (56–58). Of note, SS is a key
element in the process of patient randomization in the
ongoing pivotal multicenter randomized EXCEL (Evalua-
tion of Xience Prime or Xience V versus Coronary Artery
Bypass Surgery for Effectiveness of Left Main Revasculari-
zation) trial, which is randomizing patients with unprotected
LM CAD and SS <32 to either PCI or CABG.
Non–ST-segment elevation acute coronary syndrome.
Palmerini et al. (16) were the ﬁrst to assess the prognostic
value of the SS in 2,627 patients with non–ST-segment
elevation acute coronary syndrome treated with PCI in the
ACUITY (Acute Catheterization and Urgent Intervention
Triage Strategy) trial. In that study, patients in the upper
tertile of SS had signiﬁcantly higher rates of ischemic events
than did patients in the lower 2 tertiles, and at 1 year, the SS
was an independent predictor of all-cause death, cardiac
death, and MI. These ﬁndings conﬁrm the prognostic value
of the SS also for ranges of SS signiﬁcantly lower than those
present in the SYNTAX trial, and extend the prognostic
value of the SS to patients with acute coronary syndromes.ST-segment elevation MI. Two studies have investigated
the prognostic utility of the SS in patients with ST-segment
elevation MI (12,14). In both studies, patients had signiﬁ-
cantly lower SS values than in the SYNTAX trial, demon-
strating the rarity of this practice outside of the SYNTAX
trial (2). In both studies, SS was an independent predictor
of 1-year death, major adverse cardiac events (MACE),
and stent thrombosis, with the highest tertile showing
signiﬁcantly higher rates of ischemic events compared with
the lower 2 tertiles. Interestingly, the SS determined before
PCI had a similar predictive value as the SS determined after
revascularization of the culprit artery. Further studies are
warranted to determine the role of SS in this particular
setting.
CABG population. In contrast to patients undergoing
PCI, SS seems not to inﬂuence clinical outcomes after
CABG. Several studies (2,19,59) have shown that both
mortality and composite ischemic outcomes in patients
undergoing CABG are independent from SS. Recently, the
CABG nested registry analysis of the SYNTAX trial
conﬁrmed no apparent association between high SS and an
adverse prognosis after CABG (21). One potential expla-
nation for these results is the fact that surgical revasculari-
zation, bypassing coronary lesions, is not affected by the
negative impact that lesion complexity in the proximal site of
the coronary tree may have in case PCI is performed.
However, 2 studies have recently suggested that the SS may
be associated with an adverse prognosis in patients with
unprotected LM CAD undergoing CABG, or in those
treated with off-pump CABG (18,20), Notwithstanding
these possible exceptions, demographic and clinical risk
factors seem to have a greater impact than angiographic
variables do in patients undergoing CABG.SYNTAX-Derived Risk Scores
One important limitation of SS is that it does not integrate
clinical variables in the scoring algorithm. Patients with
equivalent scores may have different short- and long-term
outcomes, depending on the presence of comorbidities
(60). To overcome these limitations, attempts have been
made to combine clinical-based scores with SS (Fig. 2,
Table 4).
Global risk classiﬁcation. The global risk classiﬁcation
(GRC), a combination of SS and EuroSCORE (European
System for Cardiac Operative Risk Evaluation), was devel-
oped to improve the predictive ability of SS (Fig. 3) (25).
Capodanno et al. (25) were the ﬁrst to demonstrate that the
GRC had signiﬁcantly better discriminative power for risk
prediction of cardiac mortality than did SS alone in patients
with multivessel CAD. Indeed, among patients with LM
CAD undergoing PCI, the GRC had a net reclassiﬁcation
improvement of 26%. In contrast to SS alone, GRC had
a better ability for discriminating patients at intermediate
risk of cardiac mortality.
Figure 2 Scores Evolving From SS
CABG ¼ coronary artery bypass graft; other abbreviations as in Figure 1.
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1225Similar results were reported by Serruys et al. (61), who
showed that GRC has a better predictive ability than
either SS alone or EuroSCORE both in patients with
unprotected LM CAD and in those with multivessel CAD.
Additionally, GRC identiﬁed a low-risk cohort of patients
that could be safely treated with PCI.
Clinical SYNTAX score. The clinical SYNTAX score
(CSS) integrates SS with the modiﬁed ACEF (Age,
Creatinine clearance and Ejection Fraction) score. Using
only 3 clinical variables, the ACEF score has been shown to
predict outcomes with comparable accuracy as that of
EuroSCORE in patients undergoing CABG (62). CSS is
determined by multiplying the SS and modiﬁed ACEF
score values. In the study by Garg et al. (26), the CSS had
a better discriminatory power for 5-year mortality and
MACE than either SS alone or modiﬁed ACEF score did.
Patients in the highest tertile of CSS had signiﬁcantly higher
rates of mortality, MACE, and repeat revascularization than
did those in the lower 2 tertiles. Moreover, CSS was an
independent predictor of MACE at 5 years. Girasis et al.
(27) reported that CSS had a better discriminatory power
and at least equivalent calibration than SS for all-cause
mortality and cardiac mortality. However, the main limita-
tions of CSS is represented by the fact that it has a poor
discriminative power for ischemic outcomes in the lower 2
tertiles and that its prognostic performance is poorer for
pooled patients with double- and triple-vessel CAD than for
patients with only triple-vessel CAD (26).
Logistic clinical SYNTAX score. In order to overcome the
above-mentioned limitations of the SS and CSS, the logisticTable 4 Comparison of SS and Derived SS Systems
Score Type Anatomical Variables Clinical Variables
SYNTAX score Yes No
Global risk classiﬁcation Yes Yes
Clinical SYNTAX score Yes Yes
Logistic clinical SYNTAX score Yes Yes
Functional SYNTAX score Yes No
SYNTAX score II Yes Yes
N/A ¼ not applicable; other abbreviations as in Tables 1 and 3.CSS was developed. SS and consequently CSS were not
developed by selecting variables in multivariable logistic
models, but rather on an arbitrary ranking of lesion site and
complexity. The logistic CSS variables were selected on the
basis of logistic regression coefﬁcients, thus developing score
charts for individual risk assessment (Fig. 4). This score
demonstrated a substantial improvement in the predictive
ability for 1-year all-cause death compared with SS, but not
for MACE. The predominant role of angiographic variables
over clinical factors in determining the risk of TVR is
a possible explanation (63). The logistic CSS has recently
been externally-validated in a different population of
patients with acute coronary syndrome (64).
Functional SYNTAX score. The rationale of integrating
fractional ﬂow reserve (FFR) measurements to SS is sup-
ported by 2 concepts highlighted by recent studies: 1)
there is a signiﬁcant discrepancy between lesion severity
assessed by visual estimation and their functional correlates as
determined by FFR (65,66); and 2) FFR-guided PCI is
associated with lower rates of adverse ischemic events in
patients with multivessel CAD compared with angiography-
guided PCI (67,68). In a recent study, the functional SS
(FSS) reclassiﬁed 39% of patients from the highest tertile
to the lower 2 tertiles, resulting in an improvement in the
discrimination power for 1-year adverse cardiovascular events
(MI, TVR, and MACE) (28). FSS was also associated
with a better inter- and intraobserver reproducibility than SS
was. Whereas FSS has the potential to be an important tool
in risk-stratiﬁcation and selection of revascularization
strategy, the lack of prospective validation, especially inPredictor of Death Predictor of MACE
Discrimination Between Lower
and Intermediate Tertiles
Yes Yes No
Yes Yes Yes
Yes Yes No
Yes Yes Yes
N/A Yes No
Yes Yes Yes
Figure 3 Nomogram Describing the Global Risk Classiﬁcation
Groups are divided as low risk (L), intermediate risk (I), and high risk (H). The SS
tertiles varied in various studies. In the study by Capodanno et al. (25), high
(EuroSCORE [European System for Cardiac Operative Risk Evaluation] >6 and SS
>27), intermediate (EuroSCORE >6 or SS >27), and low (EuroSCORE <6 and
SS 27). In the study by Serruys et al. (61), low (SS <33 and EuroSCORE <6),
intermediate (SS <33 and EuroSCORE 6 or SS 33 and EuroSCORE <6), and
high (SS 33 and EuroSCORE 6). Adapted with permission from Capodanno
et al. (25). Abbreviations as in Figure 1.
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and the fact that it may be time-consuming to perform,
limit the broad applicability of this score in daily clinical
practice.
Residual SYNTAX score. Some studies have suggested
that incomplete revascularization is among the main factors
associated with an increased risk of adverse ischemic
outcomes after PCI in patients with high SS (5). The
residual SYNTAX score (rSS) was recently proposed as
a method to systemically characterize and quantify residual
CAD after PCI (69). The rSS calculation is similar to the SS
calculation in every respect, except that it is computed after
PCI. Among the patients presenting with acute coronary
syndrome undergoing PCI, rSS was found to be an inde-
pendent predictor of mortality, cardiac mortality, MI,Figure 4 The Logistic CSS for 1-Year All-Cause Mortality Prediction
*SYNTAX-like patient deﬁned as patient having stable multivessel disease and/or left m
clearance; CSS ¼ clinical SYNTAX score; LV ¼ left ventricular; other abbreviations as inunplanned revascularization, and MACE at 1 year (Fig. 5)
(69). The predictive and discriminative abilities of rSS were
similar to the baseline SS for all outcomes except MI, for
which the baseline SS was superior. In an all-comers pop-
ulation undergoing LMCAD revascularization, rSS was also
shown to be an independent predictor of mortality at 1 year
(70). Recently, the rSS was also validated in the randomized
SYNTAX trial, where the rSS was shown to be a strong
independent predictor of 5-year mortality, with similar effects
among different subgroups (unprotected left main, diabetes,
poor ejection fraction) (71). In this analysis, the rSS demon-
strated greater discrimination and predictive value for adverse
events including death, cardiac death, stent thrombosis, and
major adverse cardiac and cerebrovascular events, compared to
baseline SS. Similar to the baseline SS, rSS aims to offer
uniform and standardized characterization of residual
CAD to help patient risk stratiﬁcation, appropriate groups
comparison, and potential revascularization strategy selection
(72,73).
CABG SYNTAX score. As the SS was initially validated
for patients with native CAD (1,2), it cannot be imple-
mented in patients with CABG. To help address this issue,
the CABG SS was developed (74). This score can be
calculated by computing ﬁrst the baseline SS of native vessels
and then subtracting points on the basis of graft function-
ality. The score was evaluated in a pilot study of 115 patients
with acceptable reproducibility (k ¼ 0.74; 95% conﬁdence
interval: 0.53 to 0.95, p < 0.001) (74). Despite the limited
power of the study, it suggested a trend toward higher all-
cause death and MACE in patients with high CABG SS.
One major limitation of this score is that it does not take
into consideration the type of graft used. At this infant stage,
the score still requires external validation in larger studies to
prove its prognostic capabilities.ain disease. Adapted with permission from Farooq et al. (63). CrCl ¼ creatinine
Figure 1.
Figure 5 Kaplan-Meier Curves Showing Events Through 1 Year
Both Kaplan-Meier curves show the signiﬁcant relation of incomplete revascularization (indicated by residual SYNTAX score [rSS]) with (A) major adverse cardiac events
(MACE) rates and (B) all-cause death. Adapted with permission from Généreux et al. (69). Abbreviations as in Figure 1.
Figure 6 Nomogram for Calculation of SS II
COPD ¼ chronic obstructive pulmonary disease; F ¼ female; LVEF ¼ left ventric-
ular ejection fraction; Left main ¼ unprotected left main coronary artery disease;
M ¼ male; PCI ¼ percutaneous coronary intervention; PVD ¼ peripheral vascular
disease; other abbreviations as in Figures 1, 2, and 4. Adapted with permission
from Farooq et al. (29).
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better guide decision-making between CABG and PCI
compared to the anatomical SS in patients with complex
CAD (29). The SS II combines the anatomical SS with
anatomical and clinical variables that were shown to alter the
threshold value of the anatomical SS so that equipoise was
achieved between CABG and PCI for long-term mortality.
These included the presence of age, creatinine clearance, left
ventricular ejection fraction, presence of unprotected LM
CAD, peripheral vascular disease, female sex, and chronic
obstructive pulmonary disease (Fig. 6). In addition the SS II
allowed for the individualized assessment of long-term
mortality in patients with LM/multivessel CAD undergoing
either PCI or CABG, compared to the grouping of risk
(low, intermediate, high) with the anatomical SS. The SS II
was developed in the randomized SYNTAX Trial and
validated in the DELTA (Drug-eluting stent for left main
coronary artery disease) registry. The proposed nomogram
for bedside application of the SS II is shown in Figure 6.
Use of SS in daily practice and clinical research. The SS
has many potential applications both in daily clinical practice
and for research purposes. First, it provides the interven-
tional cardiology community a powerful stratiﬁcation tool,
allowing uniform, standardized assessment of CAD extent
and severity. Second, the SS may guide clinicians who are
deciding upon the most appropriate revascularization
modality, especially in complex CAD, and this fact has been
recently endorsed in both American and European coronary
revascularization guidelines (Class IIa recommendation)
(56–58). This clearly justiﬁes the score’s integration in
the routine clinical practice when facing a complex CAD
dilemma. Third, as in the multinational EXCEL trial, it
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ifying patients to be enrolled in randomized controlled trials.
Finally, its ability to predict post-procedural outcomes has
important clinical implications, especially when informing
patients and family regarding potential adverse outcomes
associated with a given revascularization strategy (75).
Current Limitations
As one would expect with any scoring system, the angio-
graphic SS does have limitations. First, the SS is a purely
angiographic score and it does not integrate clinical variables
that may be relevant for risk stratiﬁcation of patients
undergoing PCI. Nonetheless, by focusing precisely on
angiographic characteristics, the SS score can adequately
summarize in a quantitative manner the complexity of
coronary anatomies that may exist across different patients.
Additionally, SS can be combined with other clinical
parameters, thereby improving its discriminatory power.
Second, SS suffers interobserver variability inherent to visual
estimation of vessel stenosis. Online quantitative coronary
angiography measurement or physiological assessment using
FFR may overcome this issue. Third, the SS score bears
other limitations inherent to angiographic characterization
of coronary lesions, such as the inability to estimate precisely
coronary plaque burden or to identify vulnerable plaques.
Whether other modalities, such as intravascular ultrasound,
optical coherence tomography, or near-infrared spectroscopy
may improve the prognostic power of SS deserves further
investigation. Fourth, SS, or any other derived scores, lacks
the capacity to take into consideration variation in patient
coronary anatomy (vessel diameter, presence and localization
of major side branches, myocardium area perfused, etc.) or the
impact of presence or absence of viability beyond stenosis.
Fifth, these scores suffer from the incapacity to appropriately
weigh major differences in operator skills, experience in
realization of complex procedures, and the impact of novel
revascularization techniques or improvement in device tech-
nology. Finally, whereas SS seems to successfully predict
several ischemic adverse events in different clinical settings,
the predictive power of individual SS components is not
known. Indeed, SS integrates heterogeneous angiographic
variables that may have a different weight in relation to
different ischemic outcomes. For example, it is possible that
calciﬁcations or lesion length are associated with TVR more
than with other ischemic outcomes, whereas the amount of
jeopardized myocardium may be a better predictor of cardiac
death. By integrating all-important angiographic variables
together with the amount of myocardium at risk, SS repre-
sents the most powerful angiographic tool to predict any
relevant cardiac endpoints.
Conclusions
The introduction of SS represented a substantial advance-
ment in the quest for better risk stratiﬁcation andprognostication of patients with CAD undergoing PCI.
Although further prospective studies are needed to better
determine SS cutoff values for risk-stratifying patients
in different clinical scenarios, the possibility of combining
clinical and anatomic variables, such as in SS II, represents
a major improvement. The role of FSS, with the possibility
of determining FFR in a noninvasive fashion using com-
puted tomography angiography (76), may help to overcome
current limitations of SS, but this possibility warrants further
investigation.
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